The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis

Siebren Dijkstra,W.P.J. Witjes,Erik P. M. Roos,Peter L. M. Vijverberg,Arno D.H. Geboers,Jos L. Bruins,G.A.H.J. Smits,Henk Vergunst,P.F.A. Mulders

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis

2016

Siebren Dijkstra
W.P.J. Witjes
Erik P. M. Roos
Peter L. M. Vijverberg
Arno D.H. Geboers
Jos L. Bruins
G.A.H.J. Smits
Henk Vergunst
P.F.A. Mulders

Purpose Compare the efficacy and tolerability of dutasteride in combination with bicalutamide to bicalutamide monotherapy in the treatment of locally advanced and metastatic prostate cancer (PCa).

Keywords:

Oncology
Biochemistry
Dutasteride
Metastatic carcinoma
PSA PROGRESSION
Prostate cancer
Prostate
Quality of life
Internal medicine
Bicalutamide
Medicine
Tolerability
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations